With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) had its target price lowered by equities researchers at Citigroup from ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for ...

Archbow Consulting announced Justine Hughes has been promoted to EVP of principal operations while Honora Gabriel and Rob ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Billionaire investor Ray Dalio says dollar bulls should worry about crypto.

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

We recently compiled a list of the 10 Best Stocks to Invest in According to Billionaire Cliff Asness. In this article, we are ...